RxDoctor Payments Data

Leslie Stelly, APRN

Family · Welsh, LANPI 1205448651

Payments from drug & device makers

$1,311in general payments, 2019–2025

Across 69 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Lilly USA, LLC$118
  • AbbVie$112
  • GSK$82
  • Genentech USA, Inc.$70
  • Axsome Therapeutics, Inc.$68
  • plus $462 from 14 others

What the payments were for

  • Food & beverage$1,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,311 in reported general payments places this provider in the 65th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$36,608
Medicare patients
223
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$72,710
JardianceEmpagliflozin36$37,140
FarxigaDapagliflozin Propanediol43$33,815
MounjaroTirzepatide22$32,100
JanuviaSitagliptin Phosphate45$31,337
TrulicityDulaglutide25$23,585
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,564
EliquisApixaban15$9,239
SymbicortBudesonide/Formoterol Fumarate14$4,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,847
Levothyroxine Sodium185$1,292
Pantoprazole Sodium111$1,291
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide71$1,241
Gabapentin60$1,076
Atorvastatin Calcium123$975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$72,71054 claims
Lilly USA, LLCMounjaro, Trulicity$118$55,68547 claims
AstraZenecaFarxiga, Symbicort$398$38,77357 claims
Boehringer IngelheimJardiance$47$37,14036 claims
GSKTrelegy Ellipta$82$11,56418 claims
PfizerEliquis$31$9,23915 claims
AbbVieSynthroid$112$89120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,610 family providers in Louisiana.

Other family in Welsh

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →